Balchem (NASDAQ:BCPC) Earns “Buy” Rating from HC Wainwright

Balchem (NASDAQ:BCPC)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $190.00 price target on the basic materials company’s stock. HC Wainwright’s price objective would suggest a potential upside of 9.45% from the company’s previous close. HC Wainwright also issued estimates for Balchem’s Q4 2026 earnings at $1.22 EPS.

Separately, StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research note on Monday, October 28th.

Balchem Trading Up 4.8 %

BCPC opened at $173.59 on Monday. Balchem has a twelve month low of $137.69 and a twelve month high of $186.03. The company has a 50-day simple moving average of $162.01 and a 200 day simple moving average of $169.44. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.64 billion, a price-to-earnings ratio of 44.17, a P/E/G ratio of 4.41 and a beta of 0.69.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings data on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The firm had revenue of $240.00 million for the quarter, compared to the consensus estimate of $239.96 million. Analysts predict that Balchem will post 4.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Balchem

Several large investors have recently bought and sold shares of the stock. Mackenzie Financial Corp lifted its stake in Balchem by 2.2% during the 4th quarter. Mackenzie Financial Corp now owns 3,840 shares of the basic materials company’s stock valued at $626,000 after acquiring an additional 84 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Balchem during the 4th quarter worth $3,246,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Balchem by 9.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 91,742 shares of the basic materials company’s stock worth $14,953,000 after purchasing an additional 8,091 shares during the period. Voloridge Investment Management LLC raised its stake in shares of Balchem by 41.0% during the 4th quarter. Voloridge Investment Management LLC now owns 26,178 shares of the basic materials company’s stock worth $4,267,000 after purchasing an additional 7,608 shares during the period. Finally, Vident Advisory LLC raised its stake in shares of Balchem by 6.0% during the 4th quarter. Vident Advisory LLC now owns 1,421 shares of the basic materials company’s stock worth $232,000 after purchasing an additional 80 shares during the period. 87.91% of the stock is currently owned by institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.